Unibest

Pharmaceutical intermediates

Darolutamide Intermediates

1 pharmaceutical intermediate for Darolutamide. Indication: Hormone-sensitive prostate cancer; Castration-sensitive prostate cancer; Prost.

Submit a ProjectAll intermediates

About Darolutamide

Originator
Orion Corporation
Indication
Hormone-sensitive prostate cancer; Castration-sensitive prostate cancer; Prost
Approved Date
07/30/2019
DS/DP
03/25/2030

Available intermediates

1 intermediate currently listed for Darolutamide. Request specifications, documentation or a quotation for any item below.

Darolutamide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Bromo-2-chlorobenzonitrile154607-01-9//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDacomitinibDanicopanDapagliflozinDaridorexant HydrochlorideDasatinib Hydrate

Building toward Darolutamide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →